£70 million investment in biotech spinout Trogenix to tackle aggressive cancers
University of Edinburgh spinout Trogenix, which is developing innovative cancer therapies, starting with brain cancer, has completed Series A financing of £70 million.
Professor Steve Pollard
The funding will enable the rapid advancement of its pipeline of potentially curative cancer therapies across multiple aggressive, treatment-resistant solid tumours into the phase 1 in-human clinical trials.
Pre-clinical studies have shown the biotech company's breakthrough Odysseus® platform can kill cancerous brain cells and stimulate the immune system, whilst leaving surrounding healthy cells and tissue untouched.
The investment is a powerful validation of the technology's potential to transform outcomes for patients facing the greatest need.
The funding round was led by IQ Capital with participation from founding investor 4BIO Capital, returning investors Cancer Research Horizons and the National Brain Tumor Society’s Brain Tumor Investment Fund, and new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital, as well as undisclosed private investors. It is Cancer Research Horizons’ largest investment to date in any company.
Initially incubated by 4BIO Capital, additional seed funding at spinout in 2023 was provided by investors including Old College Capital (OCC), the University of Edinburgh’s venture investment fund, and continues to be OCC’s largest ever Seed-stage commitment.
